Pediatric formulation issues identified in Paediatric Investigation Plans

Area of Science:

• Pharmaceutical Sciences
• Regulatory Affairs
• Pediatric Drug Development

Background:

• The European Paediatric Regulation (2007) mandates pediatric investigation plans (PIPs) for new medicinal products.
• Applicants must propose age-appropriate formulations for pediatric populations.
• Regulatory review identifies discrepancies between proposed and acceptable pediatric formulations.

Purpose of the Study:

• To review discrepancies in pediatric formulation proposals within PIP applications.
• To analyze issues identified by the Formulation Working Group (FWG) in PIP assessments.
• To provide recommendations for improving pediatric drug development processes.

Main Methods:

• Analysis of a sample of PIP applications assessed by the FWG in 2009.
• Review of formulation issues related to excipients, route of administration, pharmaceutical form, dosing accuracy, and patient acceptability.
• Assessment of 43% of validated PIP applications from 2009.

Main Results:

• Ninety-two percent of assessed formulations presented at least one issue.
• Common issues included problems with excipients, route/form of administration, dosing accuracy, and patient acceptability.
• Significant discrepancies exist between industry proposals and regulatory expectations for pediatric formulations.

Conclusions:

• A stronger focus on formulation aspects is crucial for pediatric drug development.
• Consideration of age range, disease severity, and treatment duration can streamline PIP processes.
• Addressing identified formulation issues can improve the quality and acceptability of pediatric medicines.